Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Bioceres Crop Solutions Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.10 |
52 Week High | US$14.05 |
52 Week Low | US$9.71 |
Beta | 0.47 |
11 Month Change | 0.91% |
3 Month Change | -1.94% |
1 Year Change | -4.64% |
33 Year Change | -20.14% |
5 Year Change | 76.75% |
Change since IPO | 126.53% |
Recent News & Updates
These 4 Measures Indicate That Bioceres Crop Solutions (NASDAQ:BIOX) Is Using Debt Extensively
Aug 03Recent updates
These 4 Measures Indicate That Bioceres Crop Solutions (NASDAQ:BIOX) Is Using Debt Extensively
Aug 03Bioceres Needs To Add Clarity Around Borrowings
Mar 23Bioceres Crop Solutions (NASDAQ:BIOX) Takes On Some Risk With Its Use Of Debt
Feb 03Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?
Oct 04Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Popularity With Investors Is Clear
Jun 21Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load
May 09Bioceres: A Resilient Small Cap With Conference Appearances After Thursday's Earnings
Sep 06Bioceres Crop Solutions jumps 15% after investor pitch
Aug 23We Think Bioceres Crop Solutions (NASDAQ:BIOX) Is Taking Some Risk With Its Debt
Apr 10Bioceres Has Not Resolved Its Major Risks And Is Growing Based On Commodities Bullishness
Mar 31Is Now The Time To Look At Buying Bioceres Crop Solutions Corp. (NASDAQ:BIOX)?
Mar 17Is Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Trading At A 21% Discount?
Nov 13Bioceres Crop Solutions (NASDAQ:BIOX) Shareholders Will Want The ROCE Trajectory To Continue
Jul 08Estimating The Intrinsic Value Of Bioceres Crop Solutions Corp. (NASDAQ:BIOX)
Jun 16What Does Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Share Price Indicate?
May 26Bioceres partners with Havanna to offer consumers HB4 wheat-based sustainable products
May 10Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?
May 05Bioceres Crop Solutions (NYSEMKT:BIOX) Shareholders Will Want The ROCE Trajectory To Continue
Apr 05Are Investors Undervaluing Bioceres Crop Solutions Corp. (NYSEMKT:BIOX) By 22%?
Mar 10Bioceres Crop Solutions (NYSEMKT:BIOX) Shareholders Booked A 53% Gain In The Last Year
Feb 12Shareholder Returns
BIOX | US Chemicals | US Market | |
---|---|---|---|
7D | 9.7% | 1.4% | -0.8% |
1Y | -4.6% | 7.2% | 21.5% |
Return vs Industry: BIOX underperformed the US Chemicals industry which returned 7.5% over the past year.
Return vs Market: BIOX underperformed the US Market which returned 22.9% over the past year.
Price Volatility
BIOX volatility | |
---|---|
BIOX Average Weekly Movement | 4.8% |
Chemicals Industry Average Movement | 5.7% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BIOX has not had significant price volatility in the past 3 months.
Volatility Over Time: BIOX's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | n/a | Federico Trucco | biocerescrops.com |
Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.
Bioceres Crop Solutions Corp. Fundamentals Summary
BIOX fundamental statistics | |
---|---|
Market cap | US$634.74m |
Earnings (TTM) | US$3.07m |
Revenue (TTM) | US$445.59m |
227.5x
P/E Ratio1.6x
P/S RatioIs BIOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIOX income statement (TTM) | |
---|---|
Revenue | US$445.59m |
Cost of Revenue | US$271.99m |
Gross Profit | US$173.60m |
Other Expenses | US$170.53m |
Earnings | US$3.07m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 10, 2024
Earnings per share (EPS) | 0.049 |
Gross Margin | 38.96% |
Net Profit Margin | 0.69% |
Debt/Equity Ratio | 69.7% |
How did BIOX perform over the long term?
See historical performance and comparison